A Quantum Leap in Drug Discovery
CEO / Co-Founder
Before co-founding GTN, Noor was an assistant professor at Aalborg University in Copenhagen working on machine learning with special interest in generative models. She has more than 50 publications and 1100+ citations and has co-authored a book on generative methods. She has won a number of grants and awards for her research.
Frank is professor at the Faculty of Sciences of Ghent University. He pioneered the use of quantum entanglement as a unifying theme for describing strongly interacting quantum many body systems, which are the most challenging systems to describe but also the most promising for future quantum technologies such as quantum computers. He built a world leading research group on applications of entanglement in quantum many body systems. He has received numerous awards, and is also distinguished visiting research chair at the Perimeter Institute for theoretical physics in Waterloo, Canada.
CTO / Co-Founder
Vid has spent the past ten years working on string theory and tensorial methods in quantum physics. He has held postdocs at University College London and the University of Vienna with pioneers in these fields. He has publications in numerous high impact journals and his work has been presented at leading conferences.
Austen Lamacraft is a University Lecturer at the Department of Physics at the University of Cambridge since 2012. Dr. Lamacraft has held a number of prestigious positions, including a Robert H. Dicke fellowship at Princeton, postdocs at Oxford and Cambridge, and was an assistant professor at the University of Virginia as a recipient of a NSF Career Award. He regularly publishes in prestigious journals such as Nature Physics and Physical Review Letters. His interdisciplinary background and experience are providing ideal support for the technology being developed at GTN.
Drug Discovery Researcher
Samar is a Ph.D. researcher at Cambridge University working on improving transparency in the prediction of chemical toxicity. She has an MSc in Drug Discovery and Development from University College London, where she graduated with distinction and received a number of awards including a prize for best academic performance.
Andrew Green (AGG) is professor of Theoretical Physics in UCL/LCN and former EPSRC Leadership Fellow. He is a CoI on the TOPNES programme grant and former Miller Visiting Research Professor at UC Berkeley. He is involved with the DTC in quantum technology at UCL and the CANES DTC at KCL. AGG has wide-ranging interests in strongly-correlated quantum systems. He has published > 30 papers including 1 Science, 1 Nature Physics, 1 Optics Letters and 10 Phys Rev Lett.
Ali (FRS) is a professor of theoretical chemistry at the University of Cambridge and a director of the Max Planck Institute for Solid State Research in Stuttgart. His research is focused on the electron correlation and the Schrödinger equations, combining quantum chemistry with Monte Carlo methods.
Andrei Konradi is an expert in small molecule drug discovery with extensive experience as life-sciences entrepreneur in the areas of drug discovery, feasibility assessment and strategies to create chemical intellectual property. Formerly, Andrei was the leader of the medicinal chemistry group at Elan Pharmaceuticals. Andrei has coinvented six drug candidates that already have been tested in clinical trials. Andrei is a coinventor on 61 issued US patents, and a coauthor of 38 scientific publications. Andrei was educated at The Scripps Research Institute (post-doctoral fellow), Berkeley (PhD), and MIT (SB).